TY - JOUR
T1 - Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
AU - Fowlkes, Ashley L.
AU - Yoon, Sarang K.
AU - Lutrick, Karen
AU - Gwynn, Lisa
AU - Burns, Joy
AU - Grant, Lauren
AU - Phillips, Andrew L.
AU - Ellingson, Katherine
AU - Ferraris, Maria V.
AU - LeClair, Lindsay B.
AU - Mathenge, Clare
AU - Yoo, Young M.
AU - Thiese, Matthew S.
AU - Gerald, Lynn B.
AU - Solle, Natasha Schaefer
AU - Jeddy, Zuha
AU - Odame-Bamfo, Leah
AU - Mak, Josephine
AU - Hegmann, Kurt T.
AU - Gerald, Joe K.
AU - Ochoa, Jezahel S.
AU - Berry, Mark
AU - Rose, Spencer
AU - Lamberte, Julie Mayo
AU - Madhivanan, Purnima
AU - Pubillones, Felipe A.
AU - Rai, Ramona P.
AU - Dunnigan, Kayan
AU - Jones, John T.
AU - Krupp, Karl
AU - Edwards, Laura J.
AU - Bedrick, Edward J.
AU - Sokol, Brian E.
AU - Lowe, Ashley
AU - McLeland-Wieser, Hilary
AU - Jovel, Krystal S.
AU - Fleary, Deanna E.
AU - Khan, Sana M.
AU - Poe, Brandon
AU - Hollister, James
AU - Lopez, Joanna
AU - Rivers, Patrick
AU - Beitel, Shawn
AU - Tyner, Harmony L.
AU - Naleway, Allison L.
AU - Olsho, Lauren E.W.
AU - Caban-Martinez, Alberto J.
AU - Burgess, Jefferey L.
AU - Thompson, Mark G.
AU - Gaglani, Manjusha
N1 - Publisher Copyright:
© 2022, MMWR Recommendations and Reports. All Rights Reserved.
PY - 2022
Y1 - 2022
N2 - The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDC’s Advisory Committee on Immunization Practices for persons aged 12–15 years (referred to as adolescents in this report) on May 12, 2021, and for children aged 5–11 years on November 2, 2021 (1–4). Realworld data on vaccine effectiveness (VE) in these age groups are needed, especially because when the B.1.1.529 (Omicron) variant became predominant in the United States in December 2021, early investigations of VE demonstrated a decline in protection against symptomatic infection for adolescents aged 12–15 years and adults* (5). The PROTECT† prospective cohort of 1,364 children and adolescents aged 5–15 years was tested weekly for SARS-CoV-2, irrespective of symptoms, and upon COVID-19–associated illness during July 25, 2021–February 12, 2022. Among unvaccinated participants (i.e., those who had received no COVID-19 vaccine doses) with any laboratory-confirmed SARS-CoV-2 infection, those with B.1.617.2 (Delta) variant infections were more likely to report COVID-19 symptoms (66%) than were those with Omicron infections (49%). Among fully vaccinated children aged 5–11 years, VE against any symptomatic and asymptomatic Omicron infection 14–82 days (the longest interval after dose 2 in this age group) after receipt of dose 2 of the Pfizer-BioNTech vaccine was 31% (95% CI = 9%–48%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local virus circulation. Among adolescents aged 12–15 years, adjusted VE 14–149 days after dose 2 was 87% (95% CI = 49%–97%) against symptomatic and asymptomatic Delta infection and 59% (95% CI = 22%–79%) against Omicron infection. Fully vaccinated participants with Omicron infection spent an average of one half day less sick in bed than did unvaccinated participants with Omicron infection. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations.
AB - The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDC’s Advisory Committee on Immunization Practices for persons aged 12–15 years (referred to as adolescents in this report) on May 12, 2021, and for children aged 5–11 years on November 2, 2021 (1–4). Realworld data on vaccine effectiveness (VE) in these age groups are needed, especially because when the B.1.1.529 (Omicron) variant became predominant in the United States in December 2021, early investigations of VE demonstrated a decline in protection against symptomatic infection for adolescents aged 12–15 years and adults* (5). The PROTECT† prospective cohort of 1,364 children and adolescents aged 5–15 years was tested weekly for SARS-CoV-2, irrespective of symptoms, and upon COVID-19–associated illness during July 25, 2021–February 12, 2022. Among unvaccinated participants (i.e., those who had received no COVID-19 vaccine doses) with any laboratory-confirmed SARS-CoV-2 infection, those with B.1.617.2 (Delta) variant infections were more likely to report COVID-19 symptoms (66%) than were those with Omicron infections (49%). Among fully vaccinated children aged 5–11 years, VE against any symptomatic and asymptomatic Omicron infection 14–82 days (the longest interval after dose 2 in this age group) after receipt of dose 2 of the Pfizer-BioNTech vaccine was 31% (95% CI = 9%–48%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local virus circulation. Among adolescents aged 12–15 years, adjusted VE 14–149 days after dose 2 was 87% (95% CI = 49%–97%) against symptomatic and asymptomatic Delta infection and 59% (95% CI = 22%–79%) against Omicron infection. Fully vaccinated participants with Omicron infection spent an average of one half day less sick in bed than did unvaccinated participants with Omicron infection. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations.
UR - http://www.scopus.com/inward/record.url?scp=85126655120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126655120&partnerID=8YFLogxK
U2 - 10.15585/mmwr.mm7111e1
DO - 10.15585/mmwr.mm7111e1
M3 - Article
C2 - 35298453
AN - SCOPUS:85126655120
SN - 0149-2195
VL - 71
SP - 422
EP - 428
JO - Morbidity and Mortality Weekly Report
JF - Morbidity and Mortality Weekly Report
IS - 11
ER -